Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BIbb7f6b70b4ce4820b6391059390d6139
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717602722/en/
Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545
Media:
Tracy Morris
media@veracyte.com
(650) 380-4413
Source: Veracyte, Inc.
